Nvidia and Eli Lilly have announced a collaborative effort to build the pharma industry's most powerful supercomputer with AI to speed up drug development and discovery.

The new system on Nvidia's DGX SuperPOD with B300 GPUs will serve as an "AI factory" to support research, manufacturing, imaging, and enterprise AI workloads.

Lilly will have the supercomputer in its own buildings in order to protect sensitive information and drive innovation. While the AI system will accelerate research, the company is plotting real drug findings into the 2030s according to regulatory cycles.

Eli Lilly and Company, global leader in the pharmaceuticals business, is joining forces with Nvidia to construct a supercomputer in-house for the sole purpose of drug discovery. The state-of-the-art AI supercomputer in pharma has been named, and it's a behemoth leap forward towards the use of artificial intelligence to support biomedical research and development.

The center will be fueled by Nvidia's DGX SuperPOD architecture on hundreds of B300 GPUs, performing huge AI model training, simulation, and data analysis. The computational capability will enable the scientists to explore enormous biological information, simulate molecular interaction, and find possible drug leads quicker than ever before. The center will also run exclusively on renewable power, which is compatible with Lilly's sustainability vision.

In contrast to most of the pharma firms outsourcing their AI programs to outside third-party cloud computing, Lilly has opted to house the supercomputer in-house. In this way, the firm is ideally positioned to contain its enormous proprietary research data and keep it under lock and key while realizing peak performance through its scientific and manufacturing processes.

The AI factory will be built way past mere molecule identification. It will help train AI models via virtual experimentation, enhance manufacturing accuracy with digital twins and robots, and enhance medical imaging and diagnostics. The move is a step by Lilly management from AI as a "support tool" to a "scientific collaborator.".

Yet while the partnership will accelerate development of early-stage drugs, analysts detail that discovering drugs is a long and highly regulated process. Clinical trials, safety testing, and cycles of commercialization ensure that medicine powered by AI may never reach patients' hands until a decade from now. Failure of #Pfizer and #BioNTech to approve the deal could be disastrous for both companies.

This partnership is part of a broader movement in the pharmaceutical world the coming together of AI, machine learning, and supercomputing to revolutionize the future of medicine. With investments pouring into AI-driven drug discovery worldwide, Lilly's partnership with Nvidia puts it in the forefront of this new era of biotechnology.